10-[2-(1 H-Indol-3-yl)-ethyl]-2-pyridin-4-yl-10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one | 1202406-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 10-[2-(1 H-Indol-3-yl)-ethyl]-2-pyridin-4-yl-10H-benzo[4,5]imidazo[1,2-a]pyrimidin-4-one
• 英文别名: 10-[2-(1H-indol-3-yl)ethyl]-2-pyridin-4-ylpyrimido[1,2-a]benzimidazol-4-one
• CAS: 1202406-75-4
• 化学式: C₂₅H₁₉N₅O
• 分子量: 405.459
• InChiKey: WGKMFMHVAHCMFB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  31
• 可旋转键数：
  4
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Substituted tricyclic derivatives against neurodegenerative diseases
  申请人：sanofi-aventis

  公开号：EP2138498A1

  公开（公告）日：2009-12-30

  wherein: wherein: Z represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a C1-6 alkyl group, a hydroxyl group, a C1-6 alkoxy group; R1 represents a 4-pyridine ring, a 4-pyrimidine ring; R2 represents a hydrogen atom; R3 represents: a hydrogen atom; a phenyl or a naphthyl group, these groups being optionally substituted, a 5, 6 or 5-6 membered heteroaromatic group, this group being optionally substituted, n represents 0 to 3; m represents 0 to 1, in form of a free base or of an addition salt with an acid. Use in therapeutic

  其中：Z代表键，羰基团，甲基桥基，该甲基桥基可选地被来自C1-6烷基、羟基、C1-6烷氧基的一或两个基团取代；R1代表4-吡啶环、4-嘧啶环；R2代表氢原子；R3代表：氢原子；苯基或萘基，这些基团可选地被取代，5、6或5-6成员的杂环芳基基团，该基团可选地被取代，n代表0到3；m代表0到1，以自由碱或与酸形成的加合物盐的形式使用于治疗。
• SUBSTITUTED TRICYCLIC DERIVATIVES
  申请人：GARCIA Antonio Almario

  公开号：US20110224220A1

  公开（公告）日：2011-09-15

  Compounds of formula (I): wherein: Z, R1, R2, R3, n, and m are as defined in the disclosure. Also disclosed are methods of preparing the compounds of formula (I) and their use in therapeutics.

  化合物的化学式（I）如下： 其中：Z，R1，R2，R3，n和m的定义如本文所述。还披露了制备化合物（I）的方法以及它们在治疗学中的应用。
• SUBSTITUTED TRICYCLIC DERIVATIVES AGAINST NEURODEGENERATIVE DISEASES
  申请人：Mitsubishi Tanabe Pharma Corporation

  公开号：EP2307416A2

  公开（公告）日：2011-04-13
• US8273758B2
  申请人：——

  公开号：US8273758B2

  公开（公告）日：2012-09-25
• [EN] SUBSTITUTED TRICYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS TRICYCLIQUES SUBSTITUÉS
  申请人：MITSUBISHI TANABE PHARMA CORP

  公开号：WO2009156863A2

  公开（公告）日：2009-12-30

  Substituted Tricyclic Derivatives, Formula (I) wherein: Z represents a bond, a carbonyl group, a methylene group optionally substituted by one or two groups chosen from a Ci-6 alkyl group, a hydroxyl group, a C-ι-6 alkoxy group; R1 represents a 4-pyridine ring, a 4-pyrimidine ring; R2 represents a hydrogen atom; R3 represents: a hydrogen atom; a phenyl or a naphthyl group, these groups being optionally substituted, a 5, 6 or 5-6 membered heteroaromatic group, this group being optionally substituted, n represents 0 to 3; m represents 0 to 1, in form of a free base or of an addition salt with an acid. Use in therapeutic